Chang R J, Mandel F P, Lu J K, Judd H L
J Clin Endocrinol Metab. 1982 Mar;54(3):490-4. doi: 10.1210/jcem-54-3-490.
The disassociation between serum LH and FSH levels in polycystic ovarian disease (PCO) has been attributed to chronic acyclic estrogen production characterized by a predominance of circulating estrone (E1). This study was designed to determine whether the administration of estrone benzoate (E1B) modulates gonadotropin release in PCO. In five normal women studied during the early follicular phase of a control and subsequent treatment cycle, daily LH and FSH levels were unaltered by E1B administered from days 2 to 6. Gonadotropin responses to LRF given on day 7 were similar during control and treatment cycles. In seven patients with PCO, the mean LH concentration (25.7 +/- 0.7 mIU/ml) and the daily pattern of release were unchanged by E1B administered for 14 days. In contrast, a progressive decline in FSH occurred in each subject. Mean FSH levels decreased significantly from a pretreatment value of 11.3 +/- 0.2 to 9.3 +/- 0.9 mIU/ml by day 2 (P less than 0.05) and 7.2 +/- 1.2 mIU/ml by day 14 (P less than 0.005) of E1B administration. The LH response to LRF in PCO was significantly greater than that observed in the normal subjects, whereas responses before, during, and after E1B administration were similar. The FSH responses to LRF in PCO subjects were comparable to those of the normal subjects. These data indicate that the administration of E1B to PCO subjects reduces FSH levels without altering LH release, thereby enhancing the disparity of gonadotropin secretion encountered in this syndrome. This finding is consistent with the hypothesis that impairment of FSH release by chronic acyclic estrogen production derived from nonglandular aromatization of circulating androgen could in large part be responsible for anovulation in PCO.
多囊卵巢疾病（PCO）患者血清促黄体生成素（LH）和促卵泡生成素（FSH）水平的解离，被认为是由于以循环雌酮（E1）占优势为特征的慢性无周期性雌激素分泌所致。本研究旨在确定苯甲酸雌酮（E1B）的给药是否会调节PCO患者的促性腺激素释放。在5名处于对照周期和随后治疗周期卵泡早期的正常女性中，从第2天至第6天给予E1B，并未改变每日的LH和FSH水平。在对照周期和治疗周期中，第7天给予促性腺激素释放激素（LRF）后，促性腺激素的反应相似。在7名PCO患者中，给予14天的E1B后，平均LH浓度（25.7±0.7 mIU/ml）及其每日释放模式未发生变化。相反，每个受试者的FSH水平都出现了逐渐下降。在给予E1B的第2天，FSH平均水平从治疗前的11.3±0.2显著降至9.3±0.9 mIU/ml（P<0.05），到第14天降至7.2±1.2 mIU/ml（P<0.005）。PCO患者对LRF的LH反应显著大于正常受试者，而在给予E1B之前、期间和之后的反应相似。PCO受试者对LRF的FSH反应与正常受试者相当。这些数据表明，给PCO受试者施用E1B可降低FSH水平，而不改变LH释放，从而加剧了该综合征中促性腺激素分泌的差异。这一发现与以下假设一致，即循环雄激素经非腺性芳香化作用产生的慢性无周期性雌激素分泌对FSH释放的损害，在很大程度上可能是PCO患者无排卵的原因。
